Lilly Just Reported More Than Half of Patients on Its New Weight Loss Drug Lost 20% of Their Body Weight — and a Third Lost 25%. Here's How the News Could Shake Up the Obesity Drug Market.
Phase three trials on Eli Lilly's new weight loss drug, TRIUMPH-2, showed strong results.
Overview
A new weight-loss drug from Eli Lilly (NYSE:LLY) may reset the bar for treating obesity and helping adults with type 2 diabetes lower their blood sugar.
The company recently released information from the results of a phase three trial on one of its new weight loss drugs called TRIUMPH-2, which contains retatrutide, a triple agonist drug that releases hormone receptors to suppress blood sugar, appetite, and more intensely target calorie burn.
Details
The trial showed promising results, with participants who took a 12 milligram (mg) dose of retatrutide losing an average of 49.6 pounds, or 20.8% of their body weight.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.